Title: Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study
Authors: Rutkowski, S ×
De Vleeschouwer, Steven
Kaempgen, E
Wolff, J E A
Kühl, J
Demaerel, Philippe
Warmuth-Metz, M
Flamen, P
Van Calenbergh, Frank
Plets, Christiaan
Sörensen, N
Opitz, A
Van Gool, Stefaan #
Issue Date: Oct-2004
Series Title: British Journal of Cancer vol:91 issue:9 pages:1656-1662
Abstract: Patients with relapsed malignant glioma have a poor prognosis. We developed a strategy of vaccination using autologous mature dendritic cells loaded with autologous tumour homogenate. In total, 12 patients with a median age of 36 years (range: 11-78) were treated. All had relapsing malignant glioma. After surgery, vaccines were given at weeks 1 and 3, and later every 4 weeks. A median of 5 (range: 2-7) vaccines was given. There were no serious adverse events except in one patient with gross residual tumour prior to vaccination, who repetitively developed vaccine-related peritumoral oedema. Minor toxicities were recorded in four out of 12 patients. In six patients with postoperative residual tumour, vaccination induced one stable disease during 8 weeks, and one partial response. Two of six patients with complete resection are in CCR for 3 years. Tumour vaccination for patients with relapsed malignant glioma is feasible and likely beneficial for patients with minimal residual tumour burden.
ISSN: 0007-0920
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Research Group Experimental Neurosurgery and Neuroanatomy
Laboratory of Clinical Immunology
Laboratory of Pediatric Immunology
Translational MRI (+)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science